Gilead Sciences today announced plans to invest approximately €7 million in the company’s Irish operations, opening a new base in Dublin and creating 140 jobs. As part of this expansion, the company will also establish a paediatric centre of excellence in Ireland.
The company is currently in the process of selecting a location for its new Dublin office, where the majority of the new positions will be based with the remaining roles located at Gilead’s existing Cork facilities. Gilead expects to fill 80 of the positions over the coming 12 months, with the remainder hired by early 2022.
Its manufacturing operations in Ireland supply countries across Europe and other parts of the world outside of the United States. The company has commenced the recruitment process and expects the positions to be filled by early 2022.
Gilead is adding positions at all levels in departments including clinical development, process development and analytical operations, legal, human resources, supply chain, information technology, facilities and engineering, and financial shared services.
Gilead’s sites in Ireland include a drug product manufacturing and packing facility in Carrigtwohill Co. Cork that manufactures and packages 22 Gilead drug products. The facility manufactures HIV and HCV solid oral products, representing 25 percent of Gilead’s total solid oral drug production. The company also has a financial shared services centre in Little Island, Co. Cork, which supports Gilead affiliates in Europe, Middle East, Asia and South America and was established 11 years ago, and a distribution centre in Dublin that distributes to 90 markets worldwide.
Welcoming the news, Tánaiste and Minister for Enterprise, Trade & Employment, Leo Varadkar said, "Gilead has been steadily growing its presence here over the last 20 years and today’s announcement underlines the company’s commitment to Ireland. This expansion shows that Ireland offers the right conditions – particularly our skilled and talented workforce – to allow companies like Gilead to grow their operations here. I wish them well in this next exciting chapter."
Vice President, Manufacturing Operations and General Manager, Gilead Sciences Ireland, David Cadogan added, "Gilead has a long record of operating in Ireland and our teams here have played a critical role in ensuring that patients in Europe and other parts of the world outside of the United States have access to our medicines. With this additional investment, we are looking forward to continuing this important work and growing our presence here in Ireland."